Literature DB >> 11716803

Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

M J Dumoulin1, D Lamontagne, G Molinaro, A Adam.   

Abstract

As a kallikrein-kinin system has been evidenced at the endothelium level, bradykinin released locally could be responsible, at least in part, for the vasodilatory effect of omapatrilat. To objectivate this potential role of bradykinin, it is important to understand the respective role of angiotensin-converting enzyme and neutral endopeptidase in the metabolism of this vasodilatory peptide, and also to define the influence of different pathophysiologic factors on the respective role of these metallopeptidases in this metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716803     DOI: 10.1007/s11906-001-0104-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  16 in total

1.  Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels.

Authors:  W González; J M Soleilhac; M C Fournié-Zaluski; B P Roques; J B Michel
Journal:  Eur J Pharmacol       Date:  1998-03-26       Impact factor: 4.432

Review 2.  The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins.

Authors:  C Blais; F Marceau; J L Rouleau; A Adam
Journal:  Peptides       Date:  2000-12       Impact factor: 3.750

3.  Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.

Authors:  M J Dumoulin; A Adam; J L Rouleau; D Lamontagne
Journal:  J Cardiovasc Pharmacol       Date:  2001-04       Impact factor: 3.105

4.  Detection of low molecular kininogen messenger RNA in human kidney.

Authors:  N Iwai; M Matsunaga; T Kita; M Tei; C Kawai
Journal:  J Hypertens Suppl       Date:  1988-12

Review 5.  Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart.

Authors:  H Gavras
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

6.  Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

Authors:  R Raut; J L Rouleau; C Blais; H Gosselin; G Molinaro; M G Sirois; Y Lepage; P Crine; A Adam
Journal:  Am J Physiol       Date:  1999-05

7.  AT(1) and AT(2) receptors in the kidney: role in disease and treatment.

Authors:  H M Siragy
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

8.  Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.

Authors:  C Blais; D Fortin; J L Rouleau; G Molinaro; A Adam
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

Review 9.  Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.

Authors:  M A Konstam
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

Review 10.  Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

Authors:  W Linz; G Wiemer; P Gohlke; T Unger; B A Schölkens
Journal:  Pharmacol Rev       Date:  1995-03       Impact factor: 25.468

View more
  1 in total

1.  Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation.

Authors:  Joseph D Raffetto; Reagan L Ross; Raouf A Khalil
Journal:  J Vasc Surg       Date:  2007-02       Impact factor: 4.268

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.